Skip to main content
Zur Rose Group AG logo

Zur Rose Group AG — Investor Relations & Filings

Ticker · ROSE ISIN · CH0042615283 LEI · 50670038OH136R5Z4663 SW Wholesale and retail trade
Open in API
Filings indexed 477 across all filing types
Latest filing 2024-04-16 Earnings Release
Country CH Switzerland
Listing SW ROSE

About Zur Rose Group AG

https://www.zurrosegroup.com/websites/z…

DocMorris AG, formerly Zur Rose Group AG, is a leading European e-commerce pharmacy. The company provides an online platform for medicines and develops digital health services. Its core strategy involves creating a comprehensive digital health ecosystem that connects patients, doctors, pharmacies, and health insurers on a single platform. The company's vision is to enable individuals to manage their health with a single click, offering integrated care and treatment solutions. Originally founded as a pharmacy wholesaler, it has evolved to focus on the digitalization of healthcare services.

Recent filings

Filing Released Lang Actions
DocMorris continues to grow in the first quarter of 2024 and creates digital access to the entire e-prescription market
Earnings Release Classification · 100% confidence The document explicitly states it is a 'Press release' detailing performance for the 'first quarter of 2024'. It includes key financial metrics (Revenue development, active customers) and confirms the 'indicative revenue and earnings forecast'. The presence of a detailed table showing financial figures for the period '1.1.-31.3.2024' compared to the previous year, along with the keyword 'Quarterly / Interim Statement', strongly indicates this is a report covering a period shorter than a full year. This aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not a full Annual Report (10-K), an Earnings Release (ER, which is usually just highlights), or a Call Transcript (CT). Q1 2024
2024-04-16 English
DocMorris continues to grow in the first quarter of 2024 and creates digital access to the entire e-prescription market
Earnings Release Classification · 100% confidence The document is explicitly titled as a "Press release" and contains key financial highlights for the "first quarter of 2024" (Q1 2024), including revenue growth figures, operational updates (e-prescription rollout), and confirmation of the outlook. This structure—a brief announcement focusing on period results without the full depth of a comprehensive report—is characteristic of an Earnings Release (ER). It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR), as it focuses on highlights and confirms the outlook rather than presenting detailed, audited financial statements typical of those longer forms. The presence of an agenda mentioning the '2024 Half-year results' further suggests this is the preliminary quarterly update. Q1 2024
2024-04-16 English
DocMorris setzt Wachstumskurs im ersten Quartal 2024 fort und schafft digitalen Zugang zum gesamten E-Rezept-Markt
Earnings Release Classification · 100% confidence The document is explicitly titled "Medienmitteilung" (Media Release) and reports on the company's performance for the "erstes Quartal 2024" (first quarter of 2024). It provides key financial highlights (revenue growth, customer numbers) and confirms the outlook, which is characteristic of an initial announcement of periodic financial results. The presence of a detailed financial table and the confirmation of the outlook strongly suggest this is an Earnings Release (ER) rather than just a brief announcement of a report (RPA/RNS). It is not the comprehensive quarterly report (IR) itself, as it focuses on highlights and outlook confirmation, typical for an ER preceding a full IR filing or conference call. Q1 2024
2024-04-16 German
DocMorris AG: DocMorris receives gematik approval for simple digital e-prescription redemption via health card
Regulatory Filings Classification · 100% confidence The document is explicitly labeled as an "Ad-hoc" announcement released on April 10, 2024, pursuant to Art. 53 LR (Listing Rules). It details a specific operational achievement (gematik approval for e-prescription redemption) and includes an agenda listing future events, including an 'Annual General Meeting'. This format—a timely, material, non-periodic disclosure of a significant business event—is characteristic of an ad-hoc release, which often falls under general regulatory disclosure requirements. Since there is no specific category for 'Ad-hoc' or 'Press Release' that isn't a financial report, and it is not a full financial report (10-K, IR), earnings release (ER), or management discussion (MDA), the most appropriate fallback category for a general regulatory announcement that doesn't fit the specific financial/corporate action codes is Regulatory Filings (RNS). The document length is substantial (7175 chars), so it is not an RPA.
2024-04-10 English
DocMorris AG: DocMorris receives gematik approval for simple digital e-prescription redemption via health card
Regulatory Filings Classification · 95% confidence The document is titled 'Ad hoc announcement pursuant to Art. 53 LR' and is a press release detailing a specific operational achievement: receiving regulatory approval (from gematik) for digital e-prescription redemption. This type of announcement, which is not a standard periodic financial report (like 10-K or IR) but rather a material, non-scheduled corporate event disclosure, fits best under the general 'Regulatory Filings' category (RNS) or potentially a specific operational update if one existed. Since it is an 'Ad hoc announcement' disclosing a significant business development (product approval and rollout), and it doesn't fit clearly into categories like ER, CAP, or LTR, RNS (Regulatory Filings) serves as the most appropriate general regulatory disclosure category for non-standard, material news releases. It is not an ER (Earnings Release) as it focuses on operational news, not financial results. It is not an AGM-R, 10-K, or IR. It is a specific operational update released via an ad-hoc mechanism, making RNS the best fit among the provided options for a general regulatory disclosure.
2024-04-10 English
DocMorris erhält gematik-Zulassung für einfache digitale E-Rezept-Einlösung per Gesundheitskarte
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'Ad hoc-Mitteilung gemäss Art. 53 KR' (Ad hoc announcement according to Art. 53 KR) and is a press release announcing a specific operational achievement (gematik approval for digital e-prescription redemption). This type of announcement, which is not a full financial report (like 10-K or IR), a management change (MANG), or a dividend notice (DIV), typically falls under general regulatory announcements or miscellaneous corporate news. Since it is a time-sensitive, non-periodic announcement required by market rules (Ad hoc), and it doesn't fit the specific categories like DIRS, CAP, or LTR, the most appropriate general regulatory/miscellaneous category is RNS (Regulatory Filings), which serves as a fallback for such official, non-standardized disclosures. It is not an ER (Earnings Release) as it discusses product approval, not financial results. It is not an RPA because it is the substantive announcement itself, not merely an announcement *about* the publication of another report.
2024-04-10 German

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.